ONCOS-102 Shows Promise in Combination Mesothelioma Treatment
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going full...
Source: Asbestos and Mesothelioma News - January 27, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Panel Recommends Standardized Talc Testing for Asbestos
A team of experts from eight different federal agencies has presented the U.S. Food and Drug Administration with preliminary recommendations to standardize the testing of talc for the presence of asbestos and other potentially harmful mineral products. The recommendations, some of which reject long-held talc industry positions, are designed to end the discrepancies in analysis of whether talc products are contaminated with cancer-causing substances. Preliminary recommendations will be part of the FDA’s public meeting on Feb. 4 to discuss and obtain scientific information on testing for asbestos in talc-based products suc...
Source: Asbestos and Mesothelioma News - January 21, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study Uncovers Drug Combination for Sarcomatoid Mesothelioma
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We don’t know ...
Source: Asbestos and Mesothelioma News - January 16, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Researchers Find Potential New Target for Mesothelioma Treatment
An international research team has identified a novel molecular target with potential to significantly improve future treatment of malignant pleural mesothelioma. The recent findings could lead to a drug that targets key genetic inhibitors often preventing a patient’s own immune system from suppressing mesothelioma tumor growth. Dr. Antonio Giordano, part of the collaborative research team, said the goal is reducing mesothelioma mortality with a combinational therapy that includes this new target. “These findings help us define molecular mechanisms that may be key to mesothelioma aggressiveness and progression,” Gior...
Source: Asbestos and Mesothelioma News - January 14, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Pleural and Peritoneal Mesothelioma Combination Can Be Managed
A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied, and poorly understood, group of patients that often is just written off,” surgical oncologist Dr. Michael Kluger at Columbia told The Mesothelioma Center at Asbestos.com. “But we’ve shown a meaningful survival.” Kluger, who specializes in ...
Source: Asbestos and Mesothelioma News - January 9, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Two drugs used in combination prove to be effective against most aggressive asbestos cancer in mice
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Currently, there are few effective treatments for malignant mesothelioma, although it has been decades since it was found that the major risk factor is exposure to asbestos. The drugs identified by CNIO researchers are being tested on other types of cancer, which can speed up clinical trials for mesothelioma. The authors identified molecular markers that could be used to determine which patients could benefit most from this new therapy, provided that it is approved. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 8, 2020 Category: Cancer & Oncology Source Type: news

Study: No Major Link Between Baby Powder, Cancer
The use of talc powder has been linked to other types of cancer, such as mesothelioma. A jury recently awarded a California couple nearly $30 million from Johnson & Johnson for the wife's mesothelioma, according to a CNN report. (Source: WebMD Health)
Source: WebMD Health - January 7, 2020 Category: Consumer Health News Source Type: news

US Officials Respond to Asbestos Issue at Tokyo 2020 Water Polo Venue
Officials with USA Water Polo are confident that organizers of the 2020 Tokyo Summer Olympics will fix an ongoing asbestos issue at the water polo venue for this year’s games. Japanese newspaper The Asahi Shimbun originally reported that officials had discovered asbestos-containing insulation in at least two locations of the Tatsumi International Swimming Center in 2017. But the human carcinogen was not removed during renovations to the arena. Exposure to asbestos is the primary cause of mesothelioma, a deadly cancer with no definitive cure. Following reports of the asbestos issue, Tokyo 2020 organizers are taking “...
Source: Asbestos and Mesothelioma News - January 6, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Genetic Research Team Receives $2.6M Grant from NIH
Dr. Michele Carbone at the University of Hawaii Cancer Center has good reason to start 2020 optimistic about advancing the treatment of malignant pleural mesothelioma. The National Institutes of Health awarded his research team a five-year, $2.6 million grant last month to continue its work linking the BAP1 gene mutation to the development of mesothelioma cancer. It may hold the key to an eventual cure. “This [grant] moves us in the right direction. There is reason to be hopeful,” Carbone told The Mesothelioma Center at Asbestos.com. “There is one thing left to do, develop the resources to cure this horrible cancer. ...
Source: Asbestos and Mesothelioma News - January 2, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study: Mesothelioma Patients with CD70 Protein Have Worse Prognosis
An international team of pathologists has identified a new protein often found on pleural mesothelioma tumor cells. The discovery could lead to a more accurate prognosis for patients and future treatment advances. Researchers found for the first time that mesothelioma patients expressing higher levels of the CD70 protein typically experience a much shorter survival, regardless of cell type or treatment type. “These markers might be useful for MPM [malignant pleural mesothelioma] prognostic evaluations, as well as targeted therapeutics,” the study authors wrote. “Further analyses in syngeneic mouse models demonstrate...
Source: Asbestos and Mesothelioma News - December 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Canadian Town of Asbestos Changing Its Name for Economics
Officials in Asbestos, Quebec, have been struggling for years to develop a new identity for the small Canadian mining town. Changing its name might do the trick. Mayor Hugues Grimard announced recently that his town in southeastern Quebec is looking for a name change in 2020, believing it could spark a much-needed economic recovery. The natural link between the town’s name and the toxic mineral — once so compelling — has become a roadblock to any future development. Exposure to asbestos can lead to deadly diseases, including mesothelioma cancer. “There is really a negative perception around asbestos,” Grimard tol...
Source: Asbestos and Mesothelioma News - December 9, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Comparative Study Reveals Best Mesothelioma Surgery
Less is usually better than more when it comes to aggressive surgery for pleural mesothelioma, according to the latest and most-extensive comparative study. Throughout the last 25 years, surgical patients typically fared better with the lung-sparing pleurectomy and decortication (P/D) than with the more radical extrapleural pneumonectomy (EPP). “We found that the P/D approach should be preferred when technically feasible,” Dr. Dimitrios Magouliotis of the General University Hospital of Larissa in Greece, told The Mesothelioma Center at Asbestos.com. “We believe now the P/D should be the first choice.” Magouliotis w...
Source: Asbestos and Mesothelioma News - December 5, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

DaSilva Building Mesothelioma Specialty Program in Orlando
Thoracic surgeon Dr. Marcelo DaSilva came to Orlando, Florida, with a lofty goal. He wants to make Central Florida a destination for patients diagnosed with malignant pleural mesothelioma. DaSilva also has the tools to make that goal a reality, building a mesothelioma specialty program at AdventHealth Orlando. “We want to make this a nationally — and internationally — recognized program,” DaSilva told The Mesothelioma Center at Asbestos.com. “People who come to Orlando will not only see Disney World, but they will see excellence in health care. We can do that here.” DaSilva was named chief of Thoracic Surgery S...
Source: Asbestos and Mesothelioma News - December 3, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Report: 1.5 Million UK Buildings Contain Asbestos [Infographic]
Asbestos may have been banned in the United Kingdom 20 years ago, but the deadly carcinogen continues to be the leading cause of occupational death, leading to 5,500 deaths in the U.K. last year. According to a new report by ResPublica, an estimated six million tons of the deadly carcinogen remain inside 1.5 million buildings in the U.K., including schools and hospitals — many of which were built prior to the 1999 ban. Exposure to asbestos is directly connected to multiple diseases, including mesothelioma, lung cancer and asbestosis. Jump to the full infographic: Asbestos Risk in UK Hospitals...
Source: Asbestos and Mesothelioma News - November 27, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Latest Mesothelioma Clinical Trial Opens at Memorial Sloan Kettering
Memorial Sloan Kettering Cancer Center in New York City has opened its latest clinical trial for patients with pleural mesothelioma, studying the effectiveness of an immunotherapy and chemotherapy combination prior to aggressive surgery. The novel feasibility study will determine if the use of Opdivo (nivolumab) with Alimta (pemetrexed) and either cisplatin or carboplatin — without delaying scheduled surgery — can significantly extend patient survival time. The hope is to duplicate earlier effectiveness of that same combination with other cancers. “It has been tried with promising results,” Memorial Sloan Kettering...
Source: Asbestos and Mesothelioma News - November 27, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news